Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice

Mia Ståhle; Johanna M.U. Silvola; Sanna Hellberg; Margreet de Vries; Paul H. A. Quax; Jeffrey Kroon; Petteri Rinne; Alwin de Jong; Heidi Liljenbäck; Nina Savisto; Anna Wickman; Erik S.G. Stroes; Seppo Ylä-Herttuala; Pekka Saukko; Tommy Abrahamsson; Knut Pettersson; Juhani Knuuti; Anne Roivainen; Antti Saraste;
Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice

Mia Ståhle
Johanna M.U. Silvola
Sanna Hellberg
Margreet de Vries
Paul H. A. Quax
Jeffrey Kroon
Petteri Rinne
Alwin de Jong
Heidi Liljenbäck
Nina Savisto
Anna Wickman
Erik S.G. Stroes
Seppo Ylä-Herttuala
Pekka Saukko
Tommy Abrahamsson
Knut Pettersson
Juhani Knuuti
Anne Roivainen
Antti Saraste
Katso/Avaa
Lataukset: 

Elsevier Inc
doi:10.1016/j.jacbts.2020.01.008
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042823708
Tiivistelmä

This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of 18F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.

Kokoelmat